Rheumatic immune-related adverse events in patients treated with immunotherapy

project manager


phd fellow

About the project

Immune checkpoint inhibitors (ICIs) are a form of immunotherapy that has led to breakthroughs in cancer treatment in recent years. ICIs work by reversing the cancer cells' negative regulation of the immune system and strengthening the immune cells' defense against cancer. As an unwanted effect, immune-related adverse events (irAEs) can occur in almost all organ systems. 5-10% of patients develop inflammatory rheumatic disease and these represent a completely new group of patients. There is a great need for more knowledge about this patient group and the RIMRA study was initiated to address the knowledge gap.

The purpose of the study is to describe the clinical presentation and disease course of rheumatic immune-related side effects and to evaluate the efficacy of anti-inflammatory treatment.

Who can participate?

Patients who have received checkpoint inhibitor treatment for cancer and who have symptoms of new-onset rheumatic disease or flare-ups of pre-existing rheumatic disease.

Recruitment of participants is ongoing until December 31, 2023.

Project arrangement

Patients are followed in RIMRA for one year and 4 study visits are performed. Clinical data and laboratory samples are collected, as well as plasma, serum and whole blood for biobanking. Patients are treated according to current treatment guidelines.


All rights reserved © REMEDY; Illustration/portrait images © Nicolas Tourrenc/Diakonhjemmet Hospital